Amondys 45

Drug Sarepta Therapeutics, Inc.
Total Payments
$4.8M
Transactions
223
Doctors
8
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $1.4M 62 3
2023 $1.3M 51 6
2022 $1.4M 52 1
2021 $666,719 58 1

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $2.6M 210 54.6%
Royalty or License $2.2M 6 45.4%
Food and Beverage $127.96 7 0.0%

Payments by Type

Research
$2.6M
210 transactions
General
$2.2M
13 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
4045-301 Sarepta Therapeutics, Inc. $2.6M 1
4045-302 Sarepta Therapeutics, Inc. $1,500 1

Top Doctors Receiving Payments for Amondys 45

Doctor Specialty Location Total Records
Unknown Atlanta, GA $4.8M 209
, MD Nephrology Miami, FL $10,500 7
, CPNP Nurse Practitioner Holbrook, NY $22.60 1
, M.D Pediatric Cardiology Stony Brook, NY $22.60 1
, NP Family New Hyde Park, NY $22.59 1
Akram Mirdamadiha Family Plano, TX $15.90 1
, MD Student in an Organized Health Care Education/Training Program Sherman, TX $15.90 1
Melissa Lee Pediatrics Hartford, CT $14.19 1
, MD Pediatric Emergency Medicine Hartford, CT $14.18 1

About Amondys 45

Amondys 45 is a drug associated with $4.8M in payments to 8 healthcare providers, recorded across 223 transactions in the CMS Open Payments database. The primary manufacturer is Sarepta Therapeutics, Inc..

Payment data is available from 2021 to 2024. In 2024, $1.4M was paid across 62 transactions to 3 doctors.

The most common payment nature for Amondys 45 is "Unspecified" ($2.6M, 54.6% of total).

Amondys 45 is associated with 2 research studies, including "4045-301" ($2.6M).